Comments
Commented by Stefan Feulner on April 7th, 2025 | 07:20 CEST
Porr AG, Globex Mining, Strategy – Exaggerated panic
After the euphoria came the sobering reality. Following the stock market rally since November, sparked by the re-election of Donald Trump as the new US president, we are now witnessing a direct destruction of capital. Since the Republican's inauguration, the US market has officially lost USD 10 trillion. It remains to be seen to what extent the strategy of punitive tariffs, the opening of trade disputes, and the disruption of supply chains will continue to shake the markets. In particular, companies that serve markets outside the US and can produce their raw materials domestically are likely to benefit the most.
Read
Commented by Fabian Lorenz on April 7th, 2025 | 07:10 CEST
New gold rocket ahead of takeover? Tocvan Ventures stock on the heels of Barrick Gold & Co.
While Donald Trump escalates the tariff war, gold continues to shine with ever-higher prices. Even Friday's correction is unlikely to change that. An ounce of gold is trading solidly above USD 3,000 – and rising. This puts gold explorers back in the spotlight for investors. A lesser-known player could become a real gold rocket in 2025: Tocvan Ventures. Its project in Mexico is at an advanced stage and is to be developed into a world-class operation. High-grade deposits have recently been reported again, which could significantly increase the gold resource. In addition, a pilot mine is to be launched in 2025, which could make the Company a takeover candidate. The stock has jumped and still has plenty of room to run higher, especially compared to peers. Currently, this represents an exciting buying opportunity.
Read
Commented by André Will-Laudien on April 7th, 2025 | 07:00 CEST
Trump tariff crash – Now is the time to pick the cherries! Steyr, Mutares, naoo AG, Deutsche Bank, and Commerzbank in focus
Donald J. Trump is making the world tremble. After he read out his list of punitive tariffs of 10 to 34% in the middle of the week, the international stock markets went into free fall. The DAX, DOW, and NASDAQ corrected by over 10% and closed at a daily low on Friday. The reason: China had imposed immediate countermeasures of 34%. A nightmare for consumers worldwide. Because on top of the inflation that has already manifested itself since Corona, there is now a further surge in prices that cannot be absorbed by anything. However, it will be costly for the Americans - they import over 70% of their goods abroad. The winners could be China and Europe if a free trade agreement is now agreed and the US is simply left out in the cold. Where are the opportunities for investors?
Read
Commented by Fabian Lorenz on April 4th, 2025 | 08:45 CEST
A bombshell for NetraMark shares: Is this the breakthrough for the AI biotech hidden gem?
Big news for NetraMark! The Company aims to revolutionize the clinical trial process for pharmaceutical and biotech companies - improving time efficiency, reducing costs, and increasing success rates. The software company has developed its own artificial intelligence for this purpose. Yesterday, NetraMark entered into a global partnership with a leading contract research organization (CRO). The partner is active in more than 60 countries with over 3,500 employees, and plans to use NetraMark's AI in its studies in the future. This could be the breakthrough for the AI specialist, potentially ending the stock's consolidation phase. With a market capitalization of less than CAD 100 million, the stock could have significant upside potential.
Read
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by Juliane Zielonka on April 4th, 2025 | 07:00 CEST
MiMedia, Porsche, and Xiaomi: A focus on innovation, dividends, and growth
The companies MiMedia, Porsche SE, and Xiaomi impressively demonstrate how innovation and strategic expansion can drive growth in different industries. The New York-based technology company MiMedia is revolutionizing the market for cloud storage solutions by integrating its platform directly into smartphones. With over 35 million preinstalled devices in the next two years, MiMedia expects high revenue potential and is targeting a rapidly growing target group in Latin America. Porsche SE reported a bumpy fiscal year and plans to pay a dividend of EUR 1.91 per preference share. Xiaomi is expanding its expertise in the field of electric vehicles. The technology group is financing the expansion of its EV division, which already generated billions in revenue last year, with a share placement of USD 5.5 billion. We provide an overview of investment opportunities.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 08:15 CEST
Leisure time in focus: TUI, naoo AG and PUMA share under the microscope
Leisure time and vacations shape the quality of life – and offer opportunities for investors. Whether travel, shared experiences, or sporty fashion, the desire for recreation, experiences, and an active lifestyle provides companies such as TUI, naoo, and PUMA inexhaustible customer groups. As a travel provider, TUI stands for the classic vacation dream and scores with package tours in the upper segment, as well as a billion-dollar cruise deal that has boosted its share price. The Swiss company naoo AG combines everything that makes up social media today in its leisure app: events, games and, most recently, influencer marketing. No wonder the share price is on a growth trajectory. PUMA has discovered the circular economy and is now combining sporty fashion with sustainability. Which strategy is most convincing to investors?
Read
Commented by Armin Schulz on April 3rd, 2025 | 07:30 CEST
Tungsten shortage as a goldmine: Why Almonty Industries is becoming a key player for NATO countries
As early as the beginning of December 2024, there were initial indications that China would impose certain restrictions on its tungsten exports. After the Chinese government further tightened export control on tungsten and molybdenum in early February 2025, Western industries have been increasingly seeking reliable alternatives. While Beijing leverages its dominance in critical metals as a geopolitical lever, companies like Almonty Industries are benefiting by building independent supply chains. With strategic partnerships, a relocation of its headquarters to the US, and the revival of one of South Korea's largest tungsten mines, the Company is positioning itself as a key player in a market characterized by scarcity and increasing demand.
Read
Commented by Fabian Lorenz on April 3rd, 2025 | 07:20 CEST
Stock set for 100% rally! Evotec, thyssenkrupp, Vidac Pharma - A golden April ahead?
Can shareholders look forward to a 100% price gain soon? If analysts have their way, this could be imminent for Evotec. However, shareholders must first mark an important date in April, as the medium-term share price performance is likely to be decided then. For Vidac Pharma, analysts see even greater upside potential, making the current price weakness an interesting entry opportunity. After all, the biotech company is making operational progress. One of the surprises of the current week is thyssenkrupp. The Company is benefiting from billions being spent in defense and infrastructure. Now, it could also benefit from Trump's tariff policies. Analysts recommend buying.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, Bayer: Three ways to health and returns
The pharmaceutical industry is booming, and three companies are set to be in the spotlight in 2025: Novo Nordisk, BioNxt Solutions, and Bayer. A common goal unites all three: To improve the health of millions of patients through innovative approaches. Investors have the opportunity to participate in their success. While their strategies differ, their focus on research, new therapies, and growth makes them exciting for investors. Novo Nordisk stands out with its obesity drug Wegovy. It reduces the risk of heart disease by 57% – a potential game changer, as obesity is a major contributor to severe cardiovascular diseases. BioNxt Solutions is leveraging fresh capital and future technologies. The Company is developing novel drug delivery systems, including sublingual films, transdermal patches, and oral tablets for autoimmune diseases like multiple sclerosis. With CAD 2.5 million from a private placement, it is ready for the next step. Bayer is pushing ahead with its broad pharmaceutical offensive. In 2025, the Leverkusen-based company will launch drugs for the treatment of cardiovascular diseases, oncology, and women's health – areas with high medical demand and market potential.
Read